GSK acquires Aiolos Bio for $1.4B, securing AIO-001, a potential asthma treatment, entering phase II clinical development.

British pharmaceutical company, GSK, has completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company specializing in respiratory and inflammatory conditions. The acquisition includes AIO-001, a long-acting anti-thymic stromal lymphopoietin monoclonal antibody set to enter phase II clinical development for treating adult patients with asthma. The deal is worth up to $1.4 billion, with GSK paying $1 billion upfront and up to $400 million in potential milestones.

February 15, 2024
10 Articles